This content requires an NEJM.org account. Create a free account now. Already have an account? Sign in .

Quick Take Free Preview

Nivolumab in Esophageal or Gastroesophageal Junction Cancer

Esophageal cancer causes more than half a million deaths each year. Neoadjuvant chemoradiotherapy followed by surgery is a widely used standard of care in resectable, locally advanced esophageal or gastroesophageal junction cancer, but the risk of recurrence is high, and the postsurgery standard of care has been surveillance. New research findings are summarized in a short video.